NMR-based metabolomics approach to study the effects of Wu-Zi-Yan-Zong-Wan on triptolide-induced oligospermia in rats.
Amino Acids
/ metabolism
Animals
Antioxidants
/ pharmacology
Apoptosis
/ drug effects
Biomarkers
/ metabolism
Diterpenes
Drugs, Chinese Herbal
/ pharmacology
Epoxy Compounds
Magnetic Resonance Spectroscopy
Male
Metabolomics
Oligospermia
/ drug therapy
Osmotic Pressure
/ drug effects
Oxidative Stress
/ drug effects
Phenanthrenes
Rats
Rats, Sprague-Dawley
Metabolomics
NMR
Oligospermia
Wu-zi-yan-zong-wan
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
30 Jan 2021
30 Jan 2021
Historique:
received:
04
02
2020
revised:
24
06
2020
accepted:
14
07
2020
pubmed:
6
9
2020
medline:
25
2
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Wu-Zi-Yan-Zong-Wan (WZYZW) is a commonly used Chinese medicinal recipe for oligozoospermia. Oligozoospermia is a common disease that harms human fertility, there is no effective therapeutic medicine at present. However, the underlying pharmacological mechanism remains unclear. Oligozoospermia rats model induced by Tripterygium glycosides (TG) was established to inspect the efficiency of WZYZW in the treatment of oligozoospermia by traditional pharmacodynamics combined with NMR-based metabolomics. Multivariate statistics were used to extracted the underlying biomarkers and metabolic pathways of WZYZW in the treatment of oligozoospermia. The results showed that TG disturbed many metabolites and metabolic pathways such as oxidative stress (choline, O-phosphocholine, betaine and ascorbate), energy metabolism in mitochondria (glucose, lactate, succinate, fumarate, 3-hydroxybutyrate and alanine), mitochondrial apoptosis markers (Bax and Bcl-2) and amino acids metabolisms (arginine, branched-chain amino acids, taurine and myo-inositol). WZYZW could significantly reverse the disturbed metabolites to their normal status by their abilities of anti-oxidation, anti-apoptosis, balancing the osmotic pressure regulatory molecules and regulating the amino acids metabolism. This study provides pharmacological basis and guidance for the clinical usage of WZYZW.
Identifiants
pubmed: 32889033
pii: S0378-8741(20)33074-9
doi: 10.1016/j.jep.2020.113192
pii:
doi:
Substances chimiques
Amino Acids
0
Antioxidants
0
Biomarkers
0
Diterpenes
0
Drugs, Chinese Herbal
0
Epoxy Compounds
0
Phenanthrenes
0
triptolide
19ALD1S53J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113192Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.